According to a recent market study published by Growth Market Reports, titled, “Global Comparator Drug Sourcing Market by Product, By Vendor Type, By End-user, and By Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 1,160.2 Million in 2022 and is anticipated to expand at a growth rate of 5.2% by 2031.

Comparator drug sourcing encompasses various activities, including, identification, procurement, quality assurance, logistics, blinding and labeling, and regulatory compliance. Key components of the global comparator drug sourcing market include:
Comparator Drug: It is a pharmaceutical product that has a similar therapeutic effect to the investigational drugs being tested in clinical trials.
Clinical Trials: Comparator drugs are used as controls in clinical trials to assess the performance of new drugs and determine their safety & efficacy.
CROs and Suppliers: These are organizations that provide services for sourcing, manufacturing, and distributing comparator drugs to support clinical trials.
Regulatory Compliance: Compliance with regulatory requirements and quality standards is required in the market to ensure the integrity of clinical trial data.
Global Reach: The market operates on a global scale to support clinical trials conducted in various regions.

Get Sample Report @ https://growthmarketreports.com/request-sample/5063

The Global Comparator Drug Sourcing Market has been segmented in terms of vendor type, end-user and region. In terms of vendor type, the Global Comparator Drug Sourcing Market is split into Clinical Trial Supplies Vendors, Specialist Comparator Sourcing Vendors, and Networks /Consortia. On the basis of end-user, the market is fragmented into Drug Manufacturers, CMO, Academic and Research Institute, and Others. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The urgency of COVID-19 vaccine and treatment development increased the demand for comparators, further straining supply chains and driving up prices. Regulatory agencies implemented several measures, such as allowing flexibility in comparator drug sourcing and usage in clinical trials, to mitigate supply chain disruptions. The pandemic accelerated the adoption of virtual and decentralized clinical trials, reducing the need for comparators and potentially impacting sourcing strategies. Some companies in the comparator drug sourcing market faced financial challenges, which led to mergers and acquisitions to ensure continuity of supply. Companies began to emphasize supply chain resilience, diversification, and risk management to prevent future disruptions. The COVID-19 pandemic highlighted vulnerabilities in the global comparator drug sourcing market and prompted adaptations to ensure the reliability of clinical trials and research.

Key Takeaways from the Study:

  • Players in the Global Comparator Drug Sourcing Market include AmerisourceBergen Corporation, Almac Group, Catalent, Inc, Clinical Services International (CSI), Clinigen Limited, MCKESSON CORPORATION, Myonex, Sharp Services, LLC, Thermo Fisher Scientific Inc., TransCelerate BioPharma Inc., and Intertek Group plc.

  • Increasing new drug development is expected to create opportunities in the coming years.
  • Based on vendor type, the market is segmented into Clinical Trial Supplies Vendors, Specialist Comparator Sourcing Vendors, and Networks /Consortia. The clinical trial supplies vendors segment is expected to hold a considerable share of the market during the forecast period, as these vendors offer a range of support, including the procurement, storage, labeling, packaging, and distribution of investigational drugs, medical devices, and other supplies that are required for clinical trials.
  • Based on end-user, the market is segmented into drug manufacturers, CMO, academic and research institute, and others. The drug manufacturers segment is expected to hold a considerable share of the market during the forecast period. Academic and research institutions have access to experts in pharmacology and drug development who understand the importance of using appropriate comparators in research; therefore, the segment is expected to hold a major share of the comparator drug-sourcing market in 2031.
  • Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.  North America accounted for a significant share of the market in 2022. Countries in Asia Pacific have diverse patient populations in terms of genetics, ethnicity, and disease prevalence. This boosts the requirement of a wide range of comparator drugs to ensure the relevance of clinical trial results. Moreover, the high incidence of chronic diseases in Asia is likely to contribute to the surge in the number of clinical trials in Asia.

Report Scope:

Report Metric

Details

Market Value in 2022

US$ 1,160.2 Million

Market Growth Rate (from 2022 to 2031)

5.2%

Historical Data

2016 & 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Vendor Type, By End-user and By Region

Key Companies Profiled

AmerisourceBergen Corporation, Almac Group, Catalent, Inc, Clinical Services International (CSI), Clinigen Limited, MCKESSON CORPORATION, Myonex, Sharp Services, LLC, Thermo Fisher Scientific Inc., TransCelerate BioPharma Inc., and Intertek Group plc.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

 

Target Audience:

  • Supply-side: Vendor, Manufacturer, Distributors, Suppliers, Retailer.

  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.